About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/27/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/27/2021.

Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors

Clinicaltrials.gov identifier NCT03935334

Recruitment Status Recruiting

First Posted May 2, 2019

Last update posted July 10, 2020

Study Description

Brief summary:

The purpose of this multicentre, randomized, double-blinded, single dose, two-way cross-over study, is to compare the pharmacokinetics (PK) and pharmacodynamic (PD) of two different doses of the biosimilar eptacog alfa (activated) with Novoseven in 48 patients, adult and children (>12 years), not bleeding, with hemophilia A or B with inhibitors. Patients will be randomized to receive either a single dose of eptacog alfa biosimilar 90 μg/kg or 270 μg/kg and one single dose of NovoSeven 90 μg/kg or 270 μg/kg, or vice versa, with doses separated by a washout period. All patients will be followed 12 months and will receive biosimilar eptacog alfa, on demand, for every bleeding episode that should occur - or - for prophylaxis, with the aim of monitoring of inhibiting antibody formation, lack of efficacy and collection of safety data.

  • Condition or Disease:Hemophilia A or B With Inhibitor
  • Intervention/Treatment: Biological: Biosimilar eptacog alfa, activated (AryoSeven)
    Biological: Eptacog alfa, activated (Novoseven)
  • Phase: Phase 3
Detailed Description

Forty-eight patients enrolled, not bleeding, will be randomized to receive two injections separated by a washout period of 3 days (t1/2 = 2.3h). Patients are centrally registered and randomized to receive in a 2x2 cross-over setting either a single dose of two for the following products: A: AryoSeven 90 µg/kg and B: NovoSeven 90 µg/kg - or - C: AryoSeven 270 µg/kg and D: NovoSeven 270 µg/kg. Patients will be hospitalized at the time of study medication administration and plasma sampling. Before any treatment, a blood sample will be obtained in all patients for testing for immunogenicity.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 48 participants
  • Allocation: Randomized
  • Intervention Model: Crossover Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Treatment
  • Official Title: A Randomized, Multicenter, Double-blind Clinical Trial Comparing Pharmacodynamic, Pharmacokinetic and Safety of a Biosimilar Eptacog Alfa (AryoSeven) and Novoseven®, in Patients With Hemophilia A or B With Inhibitors.
  • Actual Study Start Date: July 2018
  • Estimated Primary Completion Date: October 2020
  • Estimated Study Completion Date: November 2020
Arms and interventions
Arm Intervention/treatment
Experimental: Eptacog alfa, biosimilar (AryoSeven)
Patients will be randomized to receive, in a 2x2 crossover setting, either a single dose of biosimilar eptacog alfa, activated (AryoSeven) of 90 μg/kg or 270 μg/kg, or eptacog alfa, activated (Novoseven) of 90 μg/kg or 270 μg/kg, or vice-versa, separated by a washout period of 3 days.
Biological: Biosimilar eptacog alfa, activated (AryoSeven)
A single dose of eptacog alfa biosimilar (AryoSeven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
Active Comparator: Novoseven
Patients will be randomized to receive, in a 2x2 crossover setting, either a single dose of biosimilar eptacog alfa, activated (AryoSeven) of 90 μg/kg or 270 μg/kg, or eptacog alfa, activated (Novoseven) of 90 μg/kg or 270 μg/kg, or vice-versa, separated by a washout period of 3 days.
Biological: Eptacog alfa, activated (Novoseven)
A single dose of eptacog alfa (Novoseven) 90 μg/kg or 270 μg/kg. Then, in an open follow up phase of 12 months, for every bleeding episode patients will receive eptacog alfa biosimilar, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
Outcome Measures
  • Primary Outcome Measures: 1. Area under the plasma concentration time curve from time 0 to infinity, based on the last observed concentration (AUCinf) [ Time Frame: Ten minutes prior to dose administration and at 10 minutes, 20 minutes, 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours and 30 hours after AryoSeven and NovoSeven injection ]
    Measurement of plasma level of factor VII clotting activity (FVII:C) determined by commercial Staclot® VIIa-recombinant tissue factor assay (Diagnostics Stago, France).
  • 2. Treatment response to Thrombin Generation Assay (TGA), D-Dimer, F1.2 prothrombin fragments. [ Time Frame: Ten minutes prior to dose administration and at 10 minutes, 20 minutes, 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours and 30 hours after AryoSeven and NovoSeven injection ]
    Measurement of plasma levels based on standard methods recommended by the Subcommittee on the control of anticoagulation of the ISTH
  • Secondary Outcome Measures: 1. Area under the plasma concentration-time curve from 0 to the last measurable time point (AUClast). [ Time Frame: Ten minutes prior to dose administration and at 10 minutes, 20 minutes, 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours and 30 hours after AryoSeven and NovoSeven injection ]
    Measurement of plasma level of factor VII clotting activity (FVII:C) determined by commercial Staclot® VIIa-recombinant tissue factor assay
  • 2. Maximum plasma concentration (Cmax) [ Time Frame: Ten minutes prior to dose administration and at 10 minutes, 20 minutes, 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours and 30 hours after AryoSeven and NovoSeven injection ]
    Measurement of plasma level of factor VII clotting activity (FVII:C) determined by commercial Staclot® VIIa-recombinant tissue factor assay
  • 3. Time of Cmax (tmax); [ Time Frame: Ten minutes prior to dose administration and at 10 minutes, 20 minutes, 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours and 30 hours after AryoSeven and NovoSeven injection ]
    Measurement of plasma level of factor VII clotting activity (FVII:C) determined by commercial Staclot® VIIa-recombinant tissue factor assay
  • 4. Fraction of the total AUCinf that was derived by extrapolation beyond tlast (AUCextra) [ Time Frame: Ten minutes prior to dose administration and at 10 minutes, 20 minutes, 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours and 30 hours after AryoSeven and NovoSeven injection ]
    Measurement of plasma level of factor VII clotting activity (FVII:C) determined by commercial Staclot® VIIa-recombinant tissue factor assay
  • 5. First order rate constant associated with the terminal (log-linear) portion of the curve (λz) [ Time Frame: Ten minutes prior to dose administration and at 10 minutes, 20 minutes, 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours and 30 hours after AryoSeven and NovoSeven injection ]
    Measurement of plasma level of factor VII clotting activity (FVII:C) determined by commercial Staclot® VIIa-recombinant tissue factor assay
  • 6. Elimination half-life [ Time Frame: Ten minutes prior to dose administration and at 10 minutes, 20 minutes, 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours and 30 hours after AryoSeven and NovoSeven injection ]
    Measurement of plasma level of factor VII clotting activity (FVII:C) determined by commercial Staclot® VIIa-recombinant tissue factor assay
  • 7. Mean residence time (MRT) [ Time Frame: Ten minutes prior to dose administration and at 10 minutes, 20 minutes, 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours and 30 hours after AryoSeven and NovoSeven injection ]
    Measurement of plasma level of factor VII clotting activity (FVII:C) determined by commercial Staclot® VIIa-recombinant tissue factor assay
  • 8. Clearance and CL/Dose (CL) [ Time Frame: Ten minutes prior to dose administration and at 10 minutes, 20 minutes, 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours and 30 hours after AryoSeven and NovoSeven injection ]
    Measurement of plasma level of factor VII clotting activity (FVII:C) determined by commercial Staclot® VIIa-recombinant tissue factor assay
  • 9. Volume of distribution (Vss) [ Time Frame: Ten minutes prior to dose administration and at 10 minutes, 20 minutes, 1 hour, 3 hours, 5 hours, 8 hours, 12 hours, 24 hours and 30 hours after AryoSeven and NovoSeven injection ]
    Measurement of plasma level of factor VII clotting activity (FVII:C) determined by commercial Staclot® VIIa-recombinant tissue factor assay
  • 10. Immunogenicity [ Time Frame: On plasma samples obtained at screening visit, before the second dose/second drug administration, and then every 3 months for a year ]
    The Prothrombin Time (PT) based Bethesda assay will be used.
  • 11. Adverse Events [ Time Frame: Adverse events (AEs) will be monitored throughout the trial, from the first dose administered up to 12 months follow-up. ]
    Information about all adverse events, whether volunteered by the patient, discovered by investigator questioning, or detected through physical examination, laboratory test or other means, will be collected, recorded and followed as appropriate.
Eligibility Criteria
  • Ages Eligible for Study: 12 Years and older (Child, Adult, Older Adult)
  • Sexes Eligible for Study: Male
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Confirmed diagnosis of congenital hemophilia A or B with inhibitors to FVIII or FIX
titer >5 Bethesda Units (BU)

- with > 2 episodes of bleeding/year requiring treatment with FVII infusions, non in
bleeding status

- male subjects

- adult and children (>12 years)

- written informed consent to the protocol to be eligible for the study. For minor
patients, parent/legal guardian will provide consent and, when possible, patient
assent will also be obtained. For compromised patients, their designated proxy must
provide informed consent.

- For the PK/PD phase, patients will be hospitalized at the time of study medication
administration for plasma sampling (2 times during the study).

Exclusion Criteria:

- Any other type of congenital or acquired coagulopathy, such as liver disease
(hepatitis), vitamin k deficiency, uremia, malignancy.

- Antibodies against Factor VII

- Ongoing bleeding prophylaxis regimens with Novoseven or planned to occur during the
trial

- Patients who have received routine (prophylactic) treatment with rFVIIa in the period
between screening visit (visit 1) and visit 2 of this study (first dose
administration)

- Platelet count less than 100.000 platelets/microliter (at screening visit)

- Any clinical sign or known history of an arterial thrombotic event or deep venous-
thrombosis or pulmonary embolism

- HIV positive with current CD4+ count of less than 200/µL

- Liver cirrhosis

- Factor VIII/IX immune tolerance induction regimen planned to occur during the trial

- Known hypersensitivity to the study medication

- Parallel participation in another experimental drug trial.

- Parallel participation in another marketed drug trial that may affect the primary
endpoint of the study

Contacts and Locations
Contacts

Contact: Amirhossein Saadatirad, PhD +98(26)36106480-84 saadatirada@aryogen.com

Locations

Iran, Islamic Republic of
Hemophilia Center - Hematology & Oncology Dept. Shiraz University of Medical Science
Shiraz

Iran, Islamic Republic of
Comprehensive Hemophilia Care Center
Teheran

Iran, Islamic Republic of
Ali Asghar Hospital
Zahedan

Turkey
Acibadem Adana Hastanesi, Pediatrik Hematoloji-Onkoloji Bölümü
Adana

Turkey
Hacettepe Üniversitesi Çocuk Sağlığı ve Hastalıkları Anabilim Dalı Çocuk Hematolojisi Bilim Dalı
Ankara

Turkey
Uludağ Üniversitesi Tıp Fakültesi Çocuk Sağlığı ve Hastalıkları Anabilim Dalı/Hematoloji Bilim Dalı
Bursa

Turkey
Istanbul Üniversitesi Cerrahpaşa Tip Fakültesi Çocuk Sağlığı ve Hastalıkları Anabilim Dalı Çocuk Hematoloji-Onkoloji B.D.
Istanbul

Turkey
Ege Üniversitesi Tip Fakültesi Cocuk Sağliği ve Hastalikari Anabilim Dali ÇocukHematoloji Bilim Dali
Izmir

Sponsors and Collaborators

AryoGen Pharmed Co.

Investigators

Study Director: Massimo Iacobelli, MD Consultant

More Information
  • Responsible Party: AryoGen Pharmed Co.
  • ClinicalTrials.gov Identifier: NCT03935334 History of Changes
  • Other Study ID Numbers: UGA 2014-01
  • First Posted: May 2, 2019 Key Record Dates
  • Last Update Posted: July 10, 2020
  • Last Verified: July 2020
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Additional relevant MeSH terms: Hemophilia A